Last deal

$19M

Amount

Series A

Stage

05.11.2007

Date

1

all rounds

$19M

Total amount

General

About Company
Ascent Therapeutics develops pepducins, a new class of drugs targeting G-protein coupled receptors.

Industry

Sector :

Subsector :

founded date

01.01.2006

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

These drugs, which work on the inside surface of cell membranes, have the potential to treat a wide range of serious illnesses, including inflammation, cancer, metabolic CNS disorders, and cardiovascular disease. Ascent Therapeutics is a biopharmaceutical company focused on rapidly generating pharmaceuticals critical to disease processes. Their innovative approach expands the GPCR frontier and offers promising treatment options for various conditions.
Contacts